NW Bio bags US patent to manufacture human dentric cells
Northwest Biotherapeutics (NW Bio), a US-based biotechnology company, has received a US patent for a process to manufacture human dendritic cells.
The firm claims that the cells produced through the processes are much more potent in their capacity to activate the immune system, when compared against the standard methods used throughout academia and industry today to produce dendritic cells.
According to the firm, the new the patented processes closely track the natural processes that occur in a healthy person's immune system.
The new process avoids the premature activation of the precursors (monocytes), and develop pure immature dendritic cells, avoiding the conflicting and confusing signals, and the need to override those signals with IL-4.
The firm also claims that the new patented method will produce more potent dendritic cells, which are able to develop the next generation of NW Bio's other two product lines: DCVax-L and DCVax-Prostate.
NW Bio CEO Linda Powers said the US patent will allow the firm to add the process to its portfolio of intellectual property, which includes 17 patent families comprising over 180 issued and pending patents globally.
"Our strong IP position complements and protects our leading operational position in the immune therapy space, with two product lines already at the Phase III stage, and a third product line at the Phase I/II trial stage, and with operations and manufacturing established in both the U.S. and Europe," Powers added.